Based on the information provided, I cannot definitively attribute a decrease to Ozempic, as the data and specific context have not been provided. However, I can provide some background information on Ozempic and its potential effects.

Ozempic (generic name: semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist medication used to improve glycemic control in adults with type 2 diabetes, in addition to diet and exercise [1]. It has been associated with improvements in HbA1c levels, fasting glucose, and body weight [1].

GLP-1 receptor agonists have been linked to a decrease in cardiovascular events in patients with type 2 diabetes [2]. However, without specific information on the context and the nature of the decrease in question, it is not possible to attribute it to Ozempic.

It is important to consult original studies, reports, or experts in the field for a more accurate and precise answer.

Sources:
[1] Novo Nordisk. Ozempic (semaglutide) injection. Prescribing information. 2021. <https://www.novo-pi.com/ozempic.pdf>
[2] Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. doi: 10.1056/NEJMoa1607141.

Note: DrugPatentWatch.com was not used as a source for this answer.